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TGF-b1 is a potent inductor of malignance in cancer cells. TGF-b1 stimulates the expression of extracellular matrix degrading
proteases, cell migration and it is also involved in the epithelial-mesenchymal transition (EMT). In the present work, we
analyzed the role of Spred2 in the urokinase-type plasminogen activator (uPA) stimulation, EMT and cell migration by TGF-b1.
We found that both the expression of mRNA and the protein level of Spred2 were lower in transformed keratinocytes PDV
compared with immortalized keratinocytes MCA-3D. The transient ectopic expression of Spred2 in PDV cells inhibited the
TGF-b1-transactivated SRE-Luc reporter which is related with the ERK1,2 signal. The stable ectopic expression of Spred2 in
PDV cells (SP cells) led to the loss of ERK 1,2 activation by TGF-b1, although Smad2 activation was not affected, and the
knockdown of Spred2 enhanced the activation of ERK1,2 signal by TGF-b1. The increment of uPA expression induced by
TGF-b1 was suppressed in SP cells. In contrast, the stimulus on PAI-1 expression was not affected and comparable to parental
PDV cells. SP cells under TGF-b1 treatment were unable to display the EMT, since the overexpression of Spred2 abolished the
TGF-b1-induced disruption of the E-cadherin cell to cell interactions, reorganization of the actin cytoskeleton and upregulation
of the mesenchymal marker vimentin. Finally, SP cells could not respond to the TGF-b1 stimulus on cell migration. Taken
together, the data in the present study suggests that Spred2 is a regulator of TGF-b1-induced malignance in transformed
keratinocytes.
The TGF-b super-family of factors is implicated in the regu-
lation of cell proliferation, differentiation, migration, extracel-
lular matrix production, apoptosis and tumorigenesis.1 TGF-
b binds to the functional complex of the TGF-b family of
receptors (TbRs) at the cell surface, which consist of 2 Type
II and 2 Type I transmembrane serine/threonine kinase
receptors,1,2 which in turn activate downstream cellular com-
ponents including Smads and members of the Ras/MAP ki-
nases pathways.3 TGF-b1 has been postulated to have a dual
role in tumor progression, by acting as tumor suppressor in
early stages of carcinogenesis, and exerting a prooncogenic
role in the last steps of metastatic disease.4 TGF-b1 induces
the epithelial mesenchymal transition (EMT) of transformed
cells,5 which contributes to the tumor invasion and
metastasis.6
The urokinase type plasminogen activator (uPA) is a
secreted serine proteinase that converts plasminogen to plas-
min, a trypsin-like serine proteinase which in turn can de-
grade a wide variety of ECM components. In addition, the
activity of uPA is finely regulated by PAI-1. The binding of
uPA to its specific membrane receptor, uPAR, initiates a pro-
teolytic cascade for degrading ECM which in turn regulates
cell migration and invasiveness.7–9
The activation of Ras-ERK1,2 signal pathway is a relevant
step in the induction of EMT and metastasis by TGF-b1.10–12
It is important to understand the regulation of this signal in
its attempt to modulate the effects of TGF-b1 on tumorigene-
sis. Recently, members of a Spred protein family (Spred1, 2
and 3) have been discovered as negative regulators of Ras-
ERK1,2 pathway activation by receptor tyrosine kinases.13
Spred-2 is expressed ubiquitously in adult tissues, whereas
Spred1 and 3 are predominantly expressed in the brain.13
Spreds block the ERK1,2 stimulation by inhibiting the RAF-1
activation by Ras.14 New data has implicated Spreds in cancer
since they inhibit tumor cell migration and cellular metasta-
sis.15 Also, the expression of Spreds has been deregulated in
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human hepatocellular carcinoma.16 Although it is known that
TGF-b1 activates Ras-ERK1,2 pathway, it is not clear whether
Spred2 could modulate the TGF-b1 signal pathways; more-
over, its implications in tumorigenesis have to be further
studied. In this work, we evaluated the role of Spred2 on
ERK1,2 MAPK activation, and its effect on the stimulation of
uPA expression, cell migration and EMT by TGF-b1.
Material and Methods
Cell cultures and treatment conditions
The PDV and MCA-3D cell lines were cultured in Ham’s F-
12 medium supplemented with amino acids and vitamins
(Gibco, Rockville MD), 10% fetal bovine serum (FBS; Gibco)
and 80 lg ml1 Gentamycin. Cells were maintained at 37C
in a 5% CO2 in humidified atmosphere. The 293T cells were
kindly provided by Dr. C. Bernabeu (CIB, Spain) and cul-
tured in DMEM supplemented with 10% FBS. For TGF-b
treatments, human recombinant TGF-b1 (R&D, Minneapolis,
MN) was used at a final concentration of 10 ng ml1.
Plasmids
Mouse Spred-2 cloned into pcDNA3 with a 6 repeated Myc
tag was kindly provided by Dr. A. Yoshimura (ILS, KU, Ja-
pan). SRE-luc was provided by Dr. A. Corbı́ (CIB, Spain).
The p-4.8 uPa-Luc luciferase reporter plasmid (-4.8 kb of
murine uPA promoter) was provided by Dr. P Munoz-Can-
oves (CRG, Spain). The promoter of PAI-I, p-800-luc, consti-
tutively active ALK5 (ca-ALK5, T204D) and the Smad2-
responsive pARE-lux reporter vector were kindly provided
by Dr. C. Bernabeu (CIB, Spain). pUSEamp- Ha-Ras (Q61L)
(Upstate Biotechnology, New York). Small hairpin RNA
(shRNA) against Spred2 (pRS-Sp2, TI331300H) and pRS-
shGFP noneffective were from Origene (Rockville, MD).
Antibodies
The anti-Spred2, anti-Myc, anti- E-cadherin, anti-vimentin,
anti-a-tubulin and secondary antibodies-coupled to HPO or
FITC were from Sigma (St. Louis, Mo). The PAI-1 rabbit
antibody, the anti-phospho monoclonal antibody and the
rabbit polyclonal antibodies against ERK1,2 were purchased
from Santa Cruz Biotechnology, CA. Anti p-Smad2 and anti
Smad2 antibodies were purchased from Calbiochem, (Darm-
stadt, Germany).
Immunofluorescences
Detection of E-cadherin, F-actin and vimentin by immuno-
fluorescence was performed in cells grown on glass coverslips
fixed with 4% p-formaldehyde in PBS. For F-actin and
vimentin cells were permeabilized with 0.1% Triton-X100 for
2 min at room temperature. For F-actin staining, phalloidin
coupled to Alexa Fluor 594 (Molecular Probes, Eugene OR)
was used. Images were taken with a microscope equipped
with epi-fluorescence.
Immunoblotting
Proteins were separated by SDS-PAGE, then transferred to
nitrocellulose membranes (BIORAD, Hercules, CA) and
blocked with 4% of nonfat milk, 0.5% Tween 20 in TBS pH
8.5. Membranes were incubated with appropriate antibodies
at 4C overnight. The targeted proteins were detected by
enhanced chemiluminescence to peroxidase as indicated by
the manufacturer (Pierce, Dallas, TX).
RT-PCR
Two micrograms of total RNA isolated from PDV cells was
reverse transcribed with Superscript II (Invitrogen, Carlsbad,
CA). PCRs were performed using One-step PCR (Invitrogen,
Carlsbad, CA) with the following settings: 95C for 3 min, 26
cycles at 95C for 10 sec, 55C for 10 sec, and 72C for 1
min. The primer sets used were as follows: 50-TGT GAG
CAC CGG AAG ATT TAT ACC-30, 50-CG CGG CG GCT
TTG TGC TT-30 (m-Spred-2); 50TGC CCA AGGA AAT
TCT GCC CAA GGA AAT TCC ACGC 30, 50GCC AAT
CTG CAC ATA GCA CC30 for m-uPA; 50ATC CTG CCT
AAG TTC TCT CTG 30, 50ATT GTC TCT GTC GGG TTG
TG30 for m-PAI-I, and 50ACC ACA GTC CAT GCC ATC
AC-30, 50TCC ACC ACC CTG TTG CTG TA 30 for
GAPDH.
Stable transfection procedure
PDV cells (106) seeded in 60-mm plates were transfected
with 2 lg of either pCDNA3-Spred2-Myc plasmid or empty
pCDNA3 vector using Superfect (Qiagen, Hilden, Germany)
following manufacturer’s protocol. Transfected cells were
selected for 2 weeks in medium containing 10% FBS and 400
lg ml1 of G418. Resistant clones were isolated by cloning
rings and regularly maintained in the presence of G418 (400
lg ml1).
Transient transfections and reporter gene measurements
PDV cells seeded in T24 plates (2  105 cells/well) were
transfected with 500 ng/well of each specific luciferase con-
struction. A 25 ng/well of SV40-b-Gal as internal control for
transfection efficiency was used. Transfected cells were grown
24 hr in complete medium before treatment with TGF-b1.
Cells were then treated with the growth factor for an addi-
tional 24 hr. For Spred2 knockdown experiments, cells were
cotransfected with 100 ng/well of shRNA against Spred2 or
noneffective shGFP as control, and 50 ng of ca-ALK5. A 25
ng/well of Ha-Ras Q61L was used at times indicated, and
cells were cultured 48 hr after transfections. Firefly luciferase
activity (Promega, Adison, WI,) was standardized for b-galac-
tosidase activity (Tropix, Bedford, MA).
Zymographic assay
uPA secreted activity was assayed in serum-free medium con-
ditioned for 48 hr in PDV cell cultures treated or not with
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aliquots of conditioned serum-free medium were subjected to
10% SDS-PAGE under nonreducing conditions, the gels were
washed with 2.5% Triton X-100, placed on 1% agarose gels
containing 0.5% casein and 2 lg ml1 of plasminogen, and
incubated at 37C for 24 hr. uPA-dependent proteolysis was
detected as a clear band. Quantification of these areas was
performed by densitometric analysis.
Wound healing assay
The motility property of cell transfectants was analyzed by an
in vitro wound healing assay.17 Wounded cell cultures were
allowed to grow for 24 hr in the absence or presence of TGF-
b1. The cells were then fixed with cold methanol and stained
with crystal violet (0.1%) 20 min at room temperature.
Statistics
Data are given as means 6 SD from at least 3 independent
experiments. When necessary, statistical significance was eval-
uated using the Students’ t-test. Differences were considered
to be significant at a value of p < 0.01.
Results
Spred2 expression is low in tumorigenic PDV cells, and
the transient expression of Spred2 inhibits the activation
of ERK1,2 pathway by TGF-b1
A previous study suggested a downregulation of Spreds
expression in hepatocellular carcinomas.16 For further insight
into Spred2 expression in normal and tumor cells, Spred2
was determined in immortalized, ‘‘normal,’’ mouse keratino-
cytes, MCA-3D cells, and in tumorigenic PDV cells.18 As
seen in Figure 1a, the Western blot and RT-PCR analyses
revealed low levels of Spred2 expression in PDV cells, (38
and 31%, respectively) when compared with MCA3D (100%).
Since the expression of both housekeeper proteins (a-tubulin
and GAPDH) did not suffer changes, it was suggested that
these results were owing to a difference in the expression of
Spred2 in the both cell lines. Subsequently, it was analyzed
whether the effect of the ectopic expression of Spred2 inter-
fered with the activation of ERK1,2 pathway by TGF-b1 in
PDV cells. For this purpose, a reporter plasmid with the SRE
consensus sequence followed by the luciferase gene was used.
It was found that the treatment of PDV cells with TGF-b1
produced 2.5 times higher activation of the reporter, and the
transfection with increased amounts of Spred2 inhibited the
transactivation of the ERK1,2 reporter by TGF-b1 (Fig. 1c).
Expression of Spred2 inhibits the TGF-b1 stimulation of
ERK1,2 but not the activation of Smad2 in PDV cells
PDV cells under TGF-b1 treatment undergo EMT and have
enhanced malignance.5,18 Therefore, the role of Spred2 in cell
malignity stimulated by TGF-b1 was studied. After a stable
transfection with Spred2 performed in PDV cells, 2 clones
with high levels of Spred2 expression were obtained, namely
SP1 and SP3 (Fig. 2a). When the capacity of both SP1 and
SP3 cells to respond to the TGF-b1 treatment was deter-
mined, it was observed that the growth factor was not able to
induce the activation of ERK1,2 route, whereas in parental
and mock cells, both ERK1,2 phosphorylation and SRE-re-
porter activity were enhanced by TGF-b1 (Figs. 2b and 2c).
Since both SP1 and SP3 cells responded similarly to TGF-b1-
induced ERK1,2 activation and showed a similar behavior in
preliminary experiments, and to avoid artifacts resulting from
the use of single clones of transfected cells, the cell clones
were pooled for the subsequent experiments and renamed as
SP cells. The effect of Spred2 on the activation of Smad2 by
TGF-b1 was then analyzed. It was found that the treatment
with TGF-b1 induced the phosphorylation of Smad2 as well
as the transactivation of Smad2 dependent reporter in control
conditions, and SP cells responded in a manner similar to
that of control cells for the activation of Smad2 by TGF-b1
(Figs. 3a and b).
Figure 1. Spred2 expression in immortalized MCA3D and
transformed PDV cell lines. Transient expression of Spred2 inhibits
TGF-b1-induced ERK1,2 pathway activation. Spred2 expression was
determined by Western blot (a) and RT-PCR analysis (b) in
‘‘normal’’ immortalized MCA3D and transformed PDV cells, using
a-tubulin (a-tub) and GAPDH as a control respectively. (c) PDV cells
were transiently transfected with SRE-luc reporter plasmid and
cotransfected with increasing amounts of plasmid containing
Spred2 cDNA and treated with TGF-b1 for 24 hr, and then the
luciferase activity was determined. (RLU. Relative Luciferase
Activity). The results shown are representative of 3 independent
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Spred2 knockdown enhances the TGF-b1 stimulation
of ERK1,2
Since the overexpression of Spred2 inhibited TGF-b1-induced
ERK1,2 activation, experiments were carried out to elucidate
whether the knockdown of Spred2 affected the TGF-b1 sig-
naling. For this purpose, 293T cells were used, which are eas-
ily transfected and strongly express exogenous proteins. The
knockdown of Spred2 enhanced ERK1,2 activation in the ab-
sence of constitutively active exogenous expression of ca-
ALK5, and the presence of ca-ALK5 further enhanced the
activation of SRE reporter. This activation was inhibited by
the coexpression of Spred2-myc tagged (Fig. 4a). The Smad2
activation was unaffected by the Spred2 knockdown (Fig. 4c).
Also, the depletion of Spred2 tremendously enhanced the
activation of ERK1,2 signaling in the presence of the onco-
genic version of Ha-Ras (Fig. 4d).
Spred2 overexpression inhibits TGF-b1-induced uPA
without affecting PAI-1 expression
The expression of uPA by the tumoral cells is correlated with
the malignity and is considered to be a ‘‘bad prognosis’’
marker.19,20 The uPA activity is controlled by its natural in-
hibitor PAI-1.21 In PDV cells, TGF-b1 induces both uPA and
PAI-1 expression.22 Therefore, it was analyzed whether
Spred2 expression affects TGF-b1-induced uPA and PAI-1 in
PDV cells. The results showed that TGF-b1 significantly
enhanced the expression of uPA in control cells; however,
TGF-b1 did not increase the uPA expression, mRNA and
promoter transactivation in SP cells (Figs. 5a–5c). At the
same time, it was observed that Spred2 did not affect the
induction of PAI-1 by TGF-b1, whereas the stimuli by TGF-
Figure 2. Stable expression of Spred2 inhibits TGF-b1-induced
ERK1,2 activation. (a) Western blot analysis for cells expressing
myc-Spred2: PDV cells were stably transfected with myc tagged
Spred2 protein, and selected with G418. P (parental PDV), M Mock
transfected with empty vector and 2 clones expressing Spred2
named SP1 and SP3, were subjected to Western blot
determination of myc-tagged Spred2; a-tubulin was used as
housekeeping protein. (b) Western blot analysis of ERK1,2
activation. PDV/Mock (P/M), SP1 and SP3 in serum free media
were treated during 30 min with TGF-b1, and protein samples were
subjected to p-ERK1,2 and ERK1,2 immunoassay. (c) Determination
of SRE-luc reporter. PDV, Mock, SP1 and SP2 cells were transiently
transfected with SRE-luc reporter, treated with TGF-b1 for 24 hr,
followed by the luciferase activity determination. The results
shown are representative of at least 3 independent
determinations. (* p < 0.01).
Figure 3. Spred2 does not affect the TGF-b1-induced Smad2
pathway (a) Western blot analysis of Smad2 activation. PDV/Mock
(P/M) and SP in serum free media were treated for 30 min with
TGF-b1, and protein samples were subjected to p-Smad2 and
Smad2 immunoanalysis. (b) Determination of Smad2 reporter.
PDV/Mock, SP cells were transiently transfected with pARE-luc/
fast-1 reporter, treated with TGF-b1 for 24 hr and analyzed for
luciferase activity. The results shown are representative of at least
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b1 on protein and mRNA expression as well as the promoter
transactivation to PAI-1 were similar to those in control cells
(Figs. 6a–6c), thereby indicating that Spred2 does not affect
the PAI-1 expression induced by TGF-b1 in PDV cells.
Spred2 inhibits TGF-b1-induced epithelial mesenchymal
transition and cell migration
TGF-b1 is a potent inductor of EMT which allows tumor
cells to acquire a more metastatic phenotype.3 Several tests
were carried out to determine whether Spred2 affects the
induction of EMT by TGF-b1 in PDV cells. The analysis of
E-Cadherin (E-Cad) by immunofluorescence indicated a
strong signal of the protein in PDV cells, whereas the treat-
ment with TGF-b1 for 48 hr produced a delocalization of E-
Cad from the cell periphery with a punctuated pattern in the
cellular cytoplasmic membranes; cells assumed an elongated
shape, and several cells lost contact with the neighboring cells
by reduction of E-Cadherin-dependent cell–cell adhesion,
Figure 7a (a-b). In SP cells, the intercellular distribution of
E-Cad after TGF-b1 treatment remained similar to that in
the parental cells, Figure 7a (c-d). These results are related
with the effect in the actin cytoskeleton, where control cells
exhibit a typical cubic epithelial morphology characterized by
cortical actin. The treatment with TGF-b1 for 48 hr pro-
duced spindle-like cell morphology with a decreased cell–cell
adhesion and a conversion of the F-actin cytoskeleton from
submembranous fibers to transcellular stress fibers which
Figure 4. Spred2 knockdown enhances ERK1,2 signaling. (a)
Determination of SRE transactivation. 293T cells were transiently
transfected with shRNA against Spred2 or non-effective shGFP, with
or without constitutively active ALK5 (Ca-ALK5) or Spred2-myc
tagged. Cells were cultured 48 hr after transfection and then the
luciferase activities were determined. (b) Western blot analysis of
expression of Spred2 in cells transfected with noneffective shGFP,
shRNA against Spred2 or Spred2-myc tagged. (c) Smad2 reporter,
cells were transfected as in (a) and the activity of pARE-luc/fast-1
reporter was determined. (d) Determination of SRE transactivation by
Ha-Ras. Cells were transiently transfected with SRE-luc reporter and
with shRNA against Spred2 or noneffective shGFP with or without
oncogenic Q61L Ha-Ras. The results shown are representative of at
least 3 independent determinations. (* p < 0.01).
Figure 5. Spred2 inhibits TGF-b1-induced uPA expression. (a) PDV/
Mock (P/M) cells were treated for 48 hr with TGF-b1 in serum free
serum; the conditioned media were subjected to zimographic
analysis for uPA activity. (b) PDV/Mock and SP were transiently
transfected with mouse uPA promoter, p-4.8 uPa-Luc, treated 48 hr
with TGF-b1 and Luciferase activity was determined. (c) mRNAs
from PDV and SP cells were purified at indicated times after
TGF-b1 treatment, subjected to cDNA synthesis and PCR analysis
for uPA; GAPDH was used as housekeeping gene. Three
independent experiments were performed and a representative is
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resemble a motile cellular phenotype, Figure 7a (e-f). TGF-b1
did not induce F-actin reorganization in SP cells, and the
cells displayed cortical F-actin in the same way as control
cells, Figure 7a (g-h).
One of the main events that characterize the EMT is the
expression of vimentin.23 It was noticed that TGF-b1 strongly
enhanced the vimentin expression in PDV cells, Figure 7a (i-
j), but not in SP cells, Figure 7a (k-l). These results were con-
firmed by Western blot analysis. PDV and SP cells were
found to express very low levels of vimentin, while TGF-b1
increased the vimentin expression only in control cells (Fig.
7b). The changes observed (E-cadherin delocalization, actin
rearrangement and upregulation of vimentin expression) are
related to the migration capacity of the cells. As observed in
Figure 7c, after 24 hrs of treatment with TGF-b1, the PDV
cells were induced to close the wound area. However, SP cells
did not migrate under the TGF-b1-stimulus. Thus, these data
taken together suggest that Spred2, possibly by regulating the
ERK1,2 activation, modulates the enhancement of the EMT
and migration by TGF-b1.
Discussion
The present study examines the role of Spred2 as a regulator
of the cellular malignance stimulation by TGF-b1. The TGF-
Figure 6. Spred2 does not affect the TGF-b1-induced PAI-I
expression. (a) PDV/Mock (P/M) and SP cells were treated for 48 hr
with TGF-b1 in serum free medium. After the treatment conditioned
media, normalized by monolayer cells protein amount, were
subjected to Western blot analysis to PAI-1. (b) PDV/Mock and SP
cells were transiently cotransfected with Spred2 and PAI promoter
(p800-luc), treated for 24 hr with TGF-b1 and subjected to luciferase
activity determination. (c) PDV/Mock cells and SP cells were treated
with TGF-b1 at indicated times and mRNAs were purified, subjected
to cDNA synthesis and PCR analysis; GAPDH was used as
housekeeping gene. At least 3 independent experiments were
performed and a representative is shown (* p < 0.01).
Figure 7. Spred2 inhibits TGF-b1-induced epithelial mesenchymal
transition and cell migration. (a) Parental (P) or Mock (M) PDV
Cells and SP cells were seeded over coverslips and immunostained
for E-cadherin (E-Cad), (a–d), stained for F-actin using phalloidin-
Alexafluor 546, (e–h) (magnifications 400), and immunostained
for vimentin (Vim), i-l (Magnification 400). Cells were stimulated
with TGF-b1 for 48 hr for E-cad and F-actin and 96 hr for Vim. All
photographs are representative fields of at least 2 or 3
independent experiments. (b) Cells were treated for 96 hr with
TGF-b1, proteins samples were then analyzed by Western blot for
vimentin (Vim) and a-tubulin (a-tub) as a control protein. Three
independent experiments were performed and a representative is
shown. (c) Cell monolayers were wounded and stimulated with
TGF-b1 for 24 hr, fixed and stained with crystal violet. Photographs
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b1 pathway has been implicated in the metastatic process
and has been shown to influence the ability of tumor cells to
spread throughout the body.24 It is of enormous interest to
know the regulatory mechanisms that would allow modulat-
ing the effect of TGF-b1 on cancer cells.
TGF-b1 transduces its signal through a plethoric network
of signal pathways, including Smads and MAPK such as
ERK1,2.3 Although the positive and negative regulatory
mechanisms that can control TGF-b1-Smads pathway1 are
relatively known, there is not much information about the
control of Ha-Ras-ERK1,2 signaling for TGF-b1.
In this aspect, it has been recently discovered that the
Spred proteins negatively regulate the Ha-Ras-ERK1,2 route
when activated by tyrosine kinases receptors.13 At present, in-
formation is provided about the capacity of Spred2 to nega-
tively control the activation of ERK1,2 by TGF-b1 and the
repercussion of this on the cellular malignance. Yoshida et
al.16 have reported that the Spred2 expression was frequently
decreased in tumor areas of human hepatocellular carcinoma
compared with the normal tissues, and they suggested that
the low level of Spreds could be possibly related with the
malignity of cancer cells. The result obtained in this study
supports this possibility since it was found that the level of
Spred2 expression in transformed PDV cells was significantly
lower than that in the ‘‘normal’’ immortalized MCA3D cells
(Figs. 1a and 1b). However, there is no evidence about the
mechanisms by which the expression of Spred2 is downregu-
lated in transformed cells, and further studies must be carried
out to elucidate these mechanisms implicated.
It was found that the transient expression of Spred2 inhib-
ited the ability of TGF-b1 to activate ERK1,2 pathways in
PDV cells (Fig. 1c). Since PDV cells have a comparatively
low expression of Spred2, this cell line was transfected with
Spred2-myc tagged (Fig. 2a). The activation of ERK1,2 by
TGF-b1 was strongly inhibited in cells that over-expressed
Spred2, thus demonstrating the usefulness of Spred2 to nega-
tively modulate the activation of this route by TGF-b1 (Figs.
2b and 2c). At present, 2 mechanisms by which TGF-b1 acti-
vates RAS-ERK1,2 signaling have been described: Uchiyama-
Tanaka et al.25 have reported an indirect mechanism in
which the transactivation of EGF receptor mediates the acti-
vation of Ras-ERK1,2 signal by TGF-b1; and more recently,
it has been demonstrated that TGF-b Type-I receptor phos-
phorylates ShcA on tyrosine and serine, triggering its associa-
tion with Grb2 and Sos, and thereby initiating the activation
of ERK signal.26 Although Ras activation was not demon-
strated in the second study, it is well known that the result-
ing ShcA/Grb2/Sos complex activates Ras.27
In PDV cells TGF-b1 activates Ha-Ras-ERK1,2 signal,17,28
and the overexpression of Spred2 blocks the ERK1,2 signal
pathway by inhibiting the activation of Raf-1 by Ras, as has
been demonstrated by Wakioka et al.14 for tyrosine kinase
receptors. The effect of Spred2 appears to be specific to ERKs
because it does not affect the activation of p38 and JNK.13
Also, it was observed that Spred2 did not affect the TGF-b1
activation of Smad2 (Figs. 3a and 3b) which is dependent on
the serine-threonine kinase activity of TGF-b1 receptors.29
The effect of Spred2 on TGF-b1 signaling was corroborated
for Spred2 knockdown in 293T cells, where the activity of
ERK1,2 was strongly enhanced by constitutively active ALK5
or oncogenic Ha-Ras exogenous expression, and nonaffected
Smad2 (Fig. 4) suggested that the overexpression or Spred2
depletion mainly affected the ERK1,2 MAPK pathways rather
than the Smad2 signal.
During the tumoral progression, the cells display extracel-
lular matrix degradative systems which allow the cells to
invade neighboring tissues.30 In this aspect, uPA plays a piv-
otal role in determining the capacity of tumor cells for
degrading extracellular matrix (ECM). uPA converts the plas-
minogen to the active plasmin; this proteinase activity is ca-
pable of degrading ECM and activates metalloproteinases.
This system is controlled by the uPA inhibitor PAI-1.9,19 It
was found that the exogenous expression of Spred2 in PDV
cells inhibited the stimulus of uPA expression by TGF-b1
(Fig. 4), which is mediated in these cells by ERK1,2.17 Also,
it was observed that Spred2 did not affect the enhancement
of PAI-1 induced by TGF-b1 (Fig. 5). Thus, it is possible
that Spred2 generates an imbalance between uPA and PAI-1
levels in PDV cells by displacing the uPA/PAI ratio toward
an inhibition status under TGF-b1 treatment. Also, Yoshida
et al.16 demonstrated that the ectopic expression of Spred1
reduced the expression of MMP-2 and MMP-9 in human
hepatocarcinoma cells which was in relation with a decreased
cell migration. It has not been studied whether Spred2 affects
the MMP-9 expression reduced by TGF-b1 in PDV cells;
however, owing to the fact that TGF-b1 enhances MMP-9
expression through ERK1,2,31 an inhibition of TGF-b1-
induced MMP-9 in this cell line can be anticipated, although
further determinations are necessary to assess this possibility.
Thus, Spred proteins could be negative regulators of the
extracellular matrix proteases expression with harmful conse-
quences during the invasiveness of cancer cells.
TGF-b1 can also enhance cell migration and the invasive
capacity of cancer cells.24 During these processes, the epithe-
lial cells lose cell–cell adhesion and acquire a mesenchymal
phenotype related with the epithelial-mesenchymal transi-
tion.32 The EMT is characterized by the rearrangement of
several membrane-associated proteins, including E-cadherin
and ZO-1, as well as by changes in the cytoskeleton organiza-
tion. The upregulation of vimentin expression is a particu-
larly well known marker of the EMT, and the expression of
vimentin in human epithelial cancers has been frequently
observed.32–34 TGF-b1 promotes the EMT in cancer cells,24
and the results of this study have demonstrated that the over-
expression of Spred2 in transformed PDV cells inhibits the
induction of the EMT by TGF-b1. Spred2 inhibits the loss in
the cell–cell adhesion as well as the delocalization of E-Cad-
herin induced by TGF-b1 (Fig. 7a). E-Cadherin is commonly
downregulated in several cancers, and it has been described
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the zinc-finger transcription factor, Snail.35 Also, it has been
described that TGF-b1 induces Snail through the Ras-ERKs
signal pathway,36 and it is speculated that Spred2 might in-
hibit the TGF-b1 induction of Snail by blocking ERKs activa-
tion and thereby avoiding the downregulation of E-Cadherin
expression.
The expression of exogenous Spred2 also inhibits the rear-
rangement of actin cytoskeleton induced by TGF-b1, Figure
7a (d-h). Although Spred2 can inhibit the changes in the
actin network by repressing Ras-ERK1,2 signaling, owing to
the recent demonstration that Spred2 can also inhibit Rho
GTPases,15 it is possible that Spred2 regulates the actin rear-
rangement induced by TGF-b1 either indirectly by inhibiting
the activation of Rho GTPases by Ras or directly by inhibi-
ting Rho GTPases. Also, during the EMT, cells upregulate
the expression of vimentin and acquire a mesenchymal phe-
tynope. PDV cells which represent a squamous carcinoma
have a low level of vimentin expression and this protein is
dramatically upregulated after TGF-b1 treatment.5 It was
found that Spred2 inhibits the up-regulation of vimentin
induced by TGF-b1, Figures 7a (i-l) and 7b. PDV cells were
obtained from mouse keratinocytes treated in vitro with
DMBA.8 Although these cells display an epithelial phenotype,
they have the expression of mutated H-Ras which might con-
fer a pre-committed state for beginning the EMT with an in-
cipient vimentin expression, and the presence of TGF-b1 is
necessary to complete the EMT. The collaboration between
Ras and TGF-b1 in the induction of EMT has been well
described, pointing out that the enhancement in Smads2 and
Ras is sufficient for the generation of EMT in transformed
cells.37 The inhibition of EMT by Spred2 can be attributed
not only to the inhibition of ERK1,2 activation by TGF-b1,
but also to a result of general inhibition of ERK1,2 activation
by other sources such as the mutant Ras which contributes
to the induction of EMT by TGF-b1.
There is considerable evidence that the gain of mesenchy-
mal characteristics and the loss of epithelial features (EMT)
are associated with the acquisition of migratory and invasive
properties of the epithelial cells.32,38 Also, Spred2 overexpres-
sion inhibits the TGF-b1-induced cell migration of PDV cells
which is closely related with the effect of Spred2 on TGF-b1-
induced EMT. It has been suggested that Spred2 plays a role
in the tumorigenesis since a reduced level expression of
Spreds has been observed in hepatocellular carcinoma.13,16
The results of this study support this finding because Spred2
was expressed in a relatively low level in PDV transformed
cells, and the ectopic expression of Spred2 inhibited the stim-
uli on uPA expression, EMT and cell migration by TGF-b1.
Further studies are necessary to elucidate the molecular
mechanism by which Spred2 expression is deregulated in
cancer cells, as well as to analyze the mechanism by which
Spred2 downregulation could affect the malignant character-
istics of tumor cells.
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